Pre-Open Stock Movers 10/12: (RRD) (TARA) (QTRX) Higher; (CVAC) (RLAY) (TREX) Lower (more...)
- Nasdaq rises after strong Microsoft forecast
- Alphabet (GOOGL) Tops EPS and Revenue Estimates But Shares Dip on YouTube and Cloud Miss, Analysts See Positive Risk/Reward Despite High Expectations
- Oil drops more than 1% as U.S. stockpiles rise sharply
- Microsoft (MSFT) Stock Gains on Strong FQ1 Results and Guidance, Analysts Raise Price Targets on Azure and Windows Outperformance
- Goldman Sachs Expects Coca-Cola (KO) Stock to Outperform Today After Strong Q3 Results
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Pre-Open Stock Movers:
R.R. Donnelley & Sons Company (NYSE: RRD) 27.4% HIGHER; Chatham Asset Management, LLC, a private investment firm which manages funds that beneficially own approximately 14.9% of the outstanding common stock and which is the largest bondholder of R.R. Donnelley & Sons Company (NYSE: RRD), today in a letter sent to RRD's Board of Directors submitted an offer to acquire all the common stock of RRD not already owned by Chatham for $7.50 per share in cash.
Protara Therapeutics, Inc. (Nasdaq: TARA) 16.6% HIGHER; announced the U.S. Food and Drug Administration (FDA) has cleared the Companys Investigational New Drug (IND) application for TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer (NMIBC). Protara expects to initiate a Phase 1 clinical trial of TARA-002 in adults with high-grade NMIBC by the end of 2021.
Quanterix Corporation (NASDAQ: QTRX) 13% HIGHER; announced today that its Simoa® phospho-Tau 181 (pTau-181) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need. The program is designed to enable accelerated development, assessment and review processes, with the intention to provide patients with more timely access to breakthrough technologies or devices.
CureVac N.V. (NASDAQ: CVAC) 14.5% LOWER; to withdraw first-generation COVID-19 vaccine.
PetVivo Holdings Inc (NASDAQ: PETV) 10% HIGHER; ThinkEquity initiates coverage with a Buy rating and a price target of $7.00.
Relay Therapeutics, Inc. (Nasdaq: RLAY) 8.9% LOWER; commenced an underwritten public offering of $350 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Relay Therapeutics.
FREYR Battery (NYSE: FREY) 8.8% HIGHER; announced the formation of a joint venture (JV) in the United States between Koch Strategic Platforms (KSP) and FREYR. The JV, which has a 50%/50% ownership structure, has been established to develop an initial 50 GWh of Gigafactory-scale battery cell manufacturing capacity in the U.S. based on 24M Technologies (24M) SemiSolid platform technology. The scale and scope of the targeted development would position the JV as one of the largest battery cell manufacturers in the U.S., using American-borne technology and the sustainable innovation of a premier U.S.-based, global industrial partner in KSP. This venture further progresses FREYRs strategic focus of developing clean, localized battery cell production and supply chains to catalyze emerging energy technology adoption.
Ocugen, Inc. (NASDAQ: OCGN) 7.5% HIGHER; panel in India recommended giving emergency use authorization for Covid-19 vaccine Covaxin for children between the ages of 2-18.
Signet Jewelers (NYSE: SIG) 5.1% HIGHER; reached an agreement to buy an off-mall US jeweler Diamonds Direct. Furthermore, Signet raised its 2022 fiscal guidance. The company previously expected Q3 and FY sales of $1.26-$1.31 and $6.80-$6.95, respectively. The updated guidance is now calling for $1.42-$1.45 and $7.04-$7.19, respectively.
Trex (NYSE: TREX) 3.9% LOWER; Baird downgraded from Outperform to Neutral with a price target of $108.00 (from $116.00) as checks suggest sell-through demand slower in Q3/Q4E.
Matson, Inc. (NYSE: MATX) 3.1% HIGHER; announces preliminary third quarter financial results, provides a business update and announces that its third quarter earnings call will be held on November 3, 2021.
Airbnb (NASDAQ: ABNB) 2.9% HIGHER; Cowen upgraded shares to Outperform from Market Perform.
Citrix Systems (NASDAQ: CTXS) 2.4% LOWER; William Blair downgraded from Outperform to Market Perform.
MGM Resorts (NYSE: MGM) 2.2% HIGHER; Credit Suisse upgraded from Neutral to Outperform with a price target of $68.00 (from $33.00).
Arch Capital Group Ltd. (NASDAQ: ACGL) 1.1% HIGHER; reports that its 2021 third quarter results will be negatively impacted by the effects of Hurricane Ida and the July flooding events in Central Europe, as well as from other minor global events
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- General Motors (GM) Beats Q3 Views, Shares Dip on EPS Outlook Miss, Analyst Remains Upbeat
- Norfolk Southern (NSC) Tops Q3 EPS by 8c
- Hertz Partners with Uber (UBER) to Add Up to 50,000 Teslas (TSLA) to Uber Network by 2023
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesCredit Suisse, William Blair, Robert W Baird, ThinkEquity, Cowen & Co, Earnings, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!